Novo Nordisk A/S (NYSE:NVO) Shares Bought by Three Bridge Wealth Advisors LLC

Three Bridge Wealth Advisors LLC raised its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 1.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 12,558 shares of the company’s stock after acquiring an additional 150 shares during the period. Three Bridge Wealth Advisors LLC’s holdings in Novo Nordisk A/S were worth $1,080,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Daiwa Securities Group Inc. acquired a new position in Novo Nordisk A/S in the 3rd quarter valued at about $28,000. Capital Performance Advisors LLP acquired a new position in shares of Novo Nordisk A/S in the third quarter valued at approximately $42,000. Carolina Wealth Advisors LLC purchased a new stake in Novo Nordisk A/S during the 3rd quarter worth approximately $48,000. Dunhill Financial LLC lifted its holdings in Novo Nordisk A/S by 196.8% during the 3rd quarter. Dunhill Financial LLC now owns 469 shares of the company’s stock worth $56,000 after buying an additional 311 shares in the last quarter. Finally, Albion Financial Group UT grew its stake in shares of Novo Nordisk A/S by 121.4% in the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after acquiring an additional 278 shares in the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

NVO has been the topic of several analyst reports. Morgan Stanley assumed coverage on Novo Nordisk A/S in a research note on Wednesday. They issued an “equal weight” rating on the stock. BMO Capital Markets decreased their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Finally, UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Stock Down 2.3 %

NVO opened at $81.78 on Thursday. The stock has a market capitalization of $366.99 billion, a P/E ratio of 24.86, a price-to-earnings-growth ratio of 0.96 and a beta of 0.45. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.75 and a current ratio of 0.74. Novo Nordisk A/S has a one year low of $78.17 and a one year high of $148.15. The business’s 50-day simple moving average is $90.45 and its 200-day simple moving average is $110.60.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Analysts anticipate that Novo Nordisk A/S will post 3.86 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be issued a $0.7874 dividend. This represents a dividend yield of 1.2%. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio is presently 21.88%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.